Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized phase II/III study of intensified alkylating agent chemotherapy with peripheral blood progenitor cell support in the preoperative chemotherapy of breast tumors that are deficient for homologous recombination.

Trial Profile

Randomized phase II/III study of intensified alkylating agent chemotherapy with peripheral blood progenitor cell support in the preoperative chemotherapy of breast tumors that are deficient for homologous recombination.

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics; Carboplatin; Cyclophosphamide; Doxorubicin; Thiotepa
  • Indications Breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 22 Jan 2021 Biomarkers information updated
  • 25 Jan 2012 Planned end date 1 Feb 2010 added as reported by ClinicalTrials.gov.
  • 02 Nov 2010 Status changed from recruiting to discontinued.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top